vs
CareDx, Inc.（CDNA）与RadNet, Inc.（RDNT）财务数据对比。点击上方公司名可切换其他公司
RadNet, Inc.的季度营收约是CareDx, Inc.的5.1倍（$547.7M vs $108.4M）。RadNet, Inc.净利率更高（-0.1% vs -3.8%，领先3.7%）。CareDx, Inc.同比增速更快（25.2% vs 14.8%）。过去两年CareDx, Inc.的营收复合增速更高（22.7% vs 12.6%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
CDNA vs RDNT — 直观对比
营收规模更大
RDNT
是对方的5.1倍
$108.4M
营收增速更快
CDNA
高出10.4%
14.8%
净利率更高
RDNT
高出3.7%
-3.8%
两年增速更快
CDNA
近两年复合增速
12.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $108.4M | $547.7M |
| 净利润 | $-4.1M | $-597.0K |
| 毛利率 | — | — |
| 营业利润率 | -5.6% | 5.1% |
| 净利率 | -3.8% | -0.1% |
| 营收同比 | 25.2% | 14.8% |
| 净利润同比 | -104.7% | -111.2% |
| 每股收益（稀释后） | $-0.08 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARDNT
| Q4 25 | $108.4M | $547.7M | ||
| Q3 25 | $100.1M | $522.9M | ||
| Q2 25 | $86.7M | $498.2M | ||
| Q1 25 | $84.7M | $471.4M | ||
| Q4 24 | $86.6M | $477.1M | ||
| Q3 24 | $82.9M | $461.1M | ||
| Q2 24 | $92.3M | $459.7M | ||
| Q1 24 | $72.0M | $431.7M |
净利润CDNARDNT
| Q4 25 | $-4.1M | $-597.0K | ||
| Q3 25 | $1.7M | $5.4M | ||
| Q2 25 | $-8.6M | $14.5M | ||
| Q1 25 | $-10.4M | $-37.9M | ||
| Q4 24 | $87.7M | $5.3M | ||
| Q3 24 | $-10.6M | $3.2M | ||
| Q2 24 | $-4.6M | $-3.0M | ||
| Q1 24 | $-19.9M | $-2.8M |
营业利润率CDNARDNT
| Q4 25 | -5.6% | 5.1% | ||
| Q3 25 | -0.2% | 5.2% | ||
| Q2 25 | -12.8% | 6.2% | ||
| Q1 25 | -15.8% | -5.1% | ||
| Q4 24 | 97.5% | 5.1% | ||
| Q3 24 | -16.6% | 7.4% | ||
| Q2 24 | -7.9% | 7.6% | ||
| Q1 24 | -31.3% | 2.6% |
净利率CDNARDNT
| Q4 25 | -3.8% | -0.1% | ||
| Q3 25 | 1.7% | 1.0% | ||
| Q2 25 | -9.9% | 2.9% | ||
| Q1 25 | -12.2% | -8.0% | ||
| Q4 24 | 101.3% | 1.1% | ||
| Q3 24 | -12.8% | 0.7% | ||
| Q2 24 | -5.0% | -0.6% | ||
| Q1 24 | -27.6% | -0.6% |
每股收益（稀释后）CDNARDNT
| Q4 25 | $-0.08 | $0.00 | ||
| Q3 25 | $0.03 | $0.07 | ||
| Q2 25 | $-0.16 | $0.19 | ||
| Q1 25 | $-0.19 | $-0.51 | ||
| Q4 24 | $1.60 | $0.08 | ||
| Q3 24 | $-0.20 | $0.04 | ||
| Q2 24 | $-0.09 | $-0.04 | ||
| Q1 24 | $-0.38 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.2M | $767.2M |
| 总债务越低越好 | — | $1.1B |
| 股东权益账面价值 | $303.1M | $1.1B |
| 总资产 | $413.2M | $3.8B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资CDNARDNT
| Q4 25 | $177.2M | $767.2M | ||
| Q3 25 | $194.2M | $804.7M | ||
| Q2 25 | $186.3M | $833.2M | ||
| Q1 25 | $230.9M | $717.3M | ||
| Q4 24 | $260.7M | $740.0M | ||
| Q3 24 | $240.9M | $748.9M | ||
| Q2 24 | $228.9M | $741.7M | ||
| Q1 24 | $215.9M | $527.0M |
总债务CDNARDNT
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $0 | $1.0B | ||
| Q2 24 | $0 | $1.0B | ||
| Q1 24 | — | $834.6M |
股东权益CDNARDNT
| Q4 25 | $303.1M | $1.1B | ||
| Q3 25 | $311.1M | $1.1B | ||
| Q2 25 | $327.4M | $932.3M | ||
| Q1 25 | $379.3M | $898.1M | ||
| Q4 24 | $378.4M | $902.3M | ||
| Q3 24 | $273.2M | $895.3M | ||
| Q2 24 | $264.7M | $881.0M | ||
| Q1 24 | $256.2M | $873.0M |
总资产CDNARDNT
| Q4 25 | $413.2M | $3.8B | ||
| Q3 25 | $432.3M | $3.7B | ||
| Q2 25 | $444.3M | $3.5B | ||
| Q1 25 | $489.6M | $3.3B | ||
| Q4 24 | $491.1M | $3.3B | ||
| Q3 24 | $477.0M | $3.3B | ||
| Q2 24 | $466.8M | $3.2B | ||
| Q1 24 | $452.4M | $3.0B |
负债/权益比CDNARDNT
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | 0.00× | 1.14× | ||
| Q2 24 | 0.00× | 1.17× | ||
| Q1 24 | — | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $84.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CDNARDNT
| Q4 25 | $21.4M | $84.2M | ||
| Q3 25 | $37.4M | $52.8M | ||
| Q2 25 | $9.9M | $120.3M | ||
| Q1 25 | $-26.6M | $41.5M | ||
| Q4 24 | $21.9M | $42.5M | ||
| Q3 24 | $12.5M | $57.4M | ||
| Q2 24 | $18.9M | $116.0M | ||
| Q1 24 | $-15.3M | $17.1M |
现金转化率CDNARDNT
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | 9.75× | ||
| Q2 25 | — | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | 7.96× | ||
| Q3 24 | — | 17.89× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
